Method for inhibiting and/or treating vaginal infection

• US 20060223765A1
• Filed: 03/30/2005
• Published: 10/05/2006
• Est. Priority Date: 03/30/2005
• Status: Abandoned Application

• Current Assignee: Kimberly-Clark Worldwide Incorporated (Kimberly-Clark Corporation)
• Original Assignee: Kimberly-Clark Worldwide Incorporated (Kimberly-Clark Corporation)
• Inventors: Huang, Lei, Yang, Shu-Ping
• Application Number:
  US11/094,496
• Publication Number:
  US 20060223765A1
• Time in Patent Office: Days
• US Class Current: 514/25
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/7032 attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
• CPC Class Codes: A61P 15/02 for disorders of the vagina

Abstract

A method for inhibiting and/or treating infection in a vagina is provided. The method comprises exposing one or more microbes to a treatment composition. The microbes are selected from the group consisting of Gardnerella, Candida, and Trichomonas, and the treatment composition comprises an effective amount of a saccharide-based nonionic surfactant. For example, in one embodiment, the saccharide-based nonionic surfactant is an alkyl glycoside.

Claims

1. A method for inhibiting and/or treating infection in a vagina, the method comprising exposing one or more microbes to a treatment composition, the microbes being selected from the group consisting of Gardnerella, Candida, and Trichomonas, the treatment composition comprising an effective amount of a saccharide-based nonionic surfactant.

2. The method of claim 1, wherein the microbes are selected from the group consisting of Gardnerella vaginalis, Candida albicans, and Trichomonas vaginalis.

3. The method of claim 1, wherein the saccharide-based nonionic surfactant is present in the treatment composition at a concentration of from about 1 to about 100 milligrams per milliliter.

4. The method of claim 1, wherein the saccharide-based nonionic surfactant is present in the treatment composition at a concentration of from about 2 to about 40 milligrams per milliliter.

5. The method of claim 1, wherein the saccharide-based nonionic surfactant is present in the treatment composition at a concentration of from about 5 to about 20 milligrams per milliliter.

6. The method of claim 1, wherein the saccharide-based nonionic surfactant has an HLB of from about 8 to about 18.

7. The method of claim 1, wherein the saccharide-based nonionic surfactant has an HLB of from about 10 to about 16.

8. The method of claim 1, wherein the saccharide-based nonionic surfactant is an alkyl glycoside having the following formula:

(Z)_n-O—

R

wherein,

Z is a saccharide residue;

n is from about 1 to about 1000; and

R is an alkyl group having 8 to 30 carbon atoms.

9. The method of claim 8, wherein Z is a residue of glucose, fructose, maltose, maltotriose, lactose, galactose, mannose, dextrose, xylose, sucrose, leucrose, or combinations thereof.

10. The method of claim 8, wherein the saccharide residue has 5 to 6 carbon atoms.

11. The method of claim 8, wherein n is from about 2 to about 6.

12. The method of claim 8, wherein the alkyl group has 8 to 20 carbon atoms.

13. The method of claim 1, wherein the saccharide-based nonionic surfactant is a fatty acid ester having the following formula:

wherein,

Z is a saccharide residue or alcohol thereof;

Y is a saccharide residue or alcohol thereof;

m is from about 1 to about 1000;

n is from about 1 to about 1000;

R₁ is an alkyl group having 8 to 30 carbon atoms; and

R₂ is an alkyl group having 8 to 30 carbon atoms.

14. The method of claim 1, wherein the saccharide-based nonionic surfactant is a glucosamide having the following formula:

wherein,

Z is a polhydroxyhydrocarbyl moiety having a linear hydrocarbyl chain with a least 3 hydroxyls directly connected to the chain, or an alkoxylated derivative thereof;

n is from about 1 to about 1000;

R₁ is H, C₁-C₄ alkyl, 2-hydroxyethyl, 2-hydroxy-propyl; and

R₂ is C₅-C₃₁ alkyl or alkenyl.

15. The method of claim 1, wherein the treatment composition further comprises a carrier in an amount greater than about 75 wt. % of the composition.

16. The method of claim 15, wherein the carrier is water.

17. The method of claim 1, wherein the treatment composition further comprises an additional surfactant, antimicrobial agent, preservative, pH modifier, anti-inflammatory agent, or combination thereof.

18. The method of claim 1, wherein the pH of the treatment composition is from about 4 to about 6.

19. The method of claim 1, further comprising administering the treatment composition into the vagina of a female who has or is at risk for a vaginal infection.

20. The method of claim 19, wherein the treatment composition is in the form of a douche formulation, lotion, cream, jelly, liniment, ointment, salve, oil, foam, gel, film, wash, suppository, slow-releasing polymer, or coating.

21. A method for inhibiting and/or treating infection in a vagina, the method comprising exposing one or more microbes to a treatment composition, the microbes being selected from the group consisting of Gardnerella vaginalis, Candida albicans, and Trichomonas vaginalis, the treatment composition comprising an effective amount of an alkyl glycoside, wherein the alkyl glycoside has the following formula:

(Z)_n-O—

R

wherein,

Z is a residue of glucose, fructose, maltose, maltotriose, lactose, galactose, mannose, dextrose, xylose, sucrose, leucrose, or combinations thereof;

n is from about 1 to about 1000; and

R is an alkyl group having 8 to 30 carbon atoms.

22. The method of claim 21, wherein the alkyl glycoside is present in the treatment composition at a concentration of from about 1 to about 20 milligrams per milliliter.

23. The method of claim 21, wherein the alkyl glycoside has an HLB of from about 8 to about 18.

24. The method of claim 21, wherein the treatment composition further comprises water in an amount greater than about 90 wt. % of the composition.

25. The method of claim 21, wherein the pH of the treatment composition is from about 4 to about 6.